BioCardia (NASDAQ:BCDA) Stock Price Up 12.1% – Time to Buy?

BioCardia, Inc. (NASDAQ:BCDA)’s stock price traded up 12.1% during trading on Friday . The company traded as high as $1.80 and last traded at $1.03. 150,596,959 shares traded hands during mid-day trading, an increase of 39,885% from the average session volume of 376,629 shares. The stock had previously closed at $0.9190.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.00.

BioCardia Trading Up 12.1%

The firm’s 50-day moving average price is $1.09 and its 200 day moving average price is $1.22. The company has a market cap of $11.72 million, a price-to-earnings ratio of -1.13 and a beta of 0.51.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Analysts forecast that BioCardia, Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of BioCardia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. DRW Securities LLC bought a new position in BioCardia in the fourth quarter worth approximately $72,000. Geode Capital Management LLC grew its stake in BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after acquiring an additional 27,263 shares during the period. Finally, Cetera Investment Advisers bought a new stake in shares of BioCardia during the second quarter valued at approximately $40,000. 20.57% of the stock is owned by institutional investors.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.